other material
confidence high
sentiment positive
materiality 0.65
Pulmatrix reports positive Phase 1b top-line data for PUR1800 in stable COPD
Pulmatrix, Inc.
- PUR1800 well-tolerated with no safety signals in 18-subject Phase 1b study.
- Preliminary PK shows low and consistent systemic exposure via oral inhalation.
- Company expects to advance PUR1800 to Phase 2 studies for AECOPD.
- Results to be submitted at a medical conference later in 2022.